Prime Medicine Financials
This page shows Prime Medicine (PRME) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Prime Medicine remains a capital-funded R&D enterprise, where cash burn and external financing matter more than early revenue.
Year-end cash of$63.0M covered less than half of the latest year's operating cash burn of$162.6M , so the balance sheet is still supporting research rather than harvesting a commercial base. That helps explain why cash still shrank even after$151.5M of financing inflow and a37.6% rise in shares outstanding.
Spending mix shows a company still built around development: R&D expense was
Earnings quality is not the main issue here; the bigger fact is that losses convert into real cash usage. Net loss of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Prime Medicine's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Prime Medicine has an operating margin of -4498.1%, meaning the company retains $-4498 of operating profit per $100 of revenue. This below-average margin results in a low score of 23/100, suggesting thin profitability after operating expenses. This is up from -6787.4% the prior year.
Prime Medicine's revenue surged 55.3% year-over-year to $4.6M, reflecting rapid business expansion. This strong growth earns a score of 95/100.
Prime Medicine has a moderate D/E ratio of 1.84. This balance of debt and equity financing earns a leverage score of 32/100.
With a current ratio of 4.84, Prime Medicine holds $4.84 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 89/100.
While Prime Medicine generated -$162.6M in operating cash flow, capex of $4.5M consumed most of it, leaving -$167.1M in free cash flow. This results in a low score of 1/100, reflecting heavy capital investment rather than weak cash generation.
Prime Medicine's ROE of -166.4% shows moderate profitability relative to equity, earning a score of 33/100. This is down from -127.9% the prior year.
Prime Medicine scores -3.54, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($581.6M) relative to total liabilities ($221.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Prime Medicine passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Prime Medicine generates $0.81 in operating cash flow (-$162.6M OCF vs -$201.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Prime Medicine generated $4.6M in revenue in fiscal year 2025. This represents an increase of 55.3% from the prior year.
Prime Medicine's EBITDA was -$201.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 2.4% from the prior year.
Prime Medicine reported -$201.1M in net income in fiscal year 2025. This represents a decrease of 2.7% from the prior year.
Prime Medicine earned $-1.35 per diluted share (EPS) in fiscal year 2025. This represents an increase of 18.2% from the prior year.
Cash & Balance Sheet
Prime Medicine generated -$167.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 28.4% from the prior year.
Prime Medicine held $63.0M in cash against $0 in long-term debt as of fiscal year 2025.
Prime Medicine had 181M shares outstanding in fiscal year 2025. This represents an increase of 37.6% from the prior year.
Margins & Returns
Prime Medicine's operating margin was -4498.1% in fiscal year 2025, reflecting core business profitability. This is up 2289.3 percentage points from the prior year.
Prime Medicine's net profit margin was -4342.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 2224.2 percentage points from the prior year.
Prime Medicine's ROE was -166.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 38.5 percentage points from the prior year.
Capital Allocation
Prime Medicine invested $160.6M in research and development in fiscal year 2025. This represents an increase of 3.4% from the prior year.
Prime Medicine invested $4.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 37.9% from the prior year.
PRME Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $838K-31.6% | $1.2M+9.9% | $1.1M-23.3% | $1.5M | N/A | $209K | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $34.1M-1.7% | $34.7M-21.1% | $44.0M+6.3% | $41.4M+2.0% | $40.6M | N/A | $40.3M-6.3% | $43.1M |
| SG&A Expenses | $17.4M+18.1% | $14.7M+31.5% | $11.2M-14.6% | $13.1M-1.3% | $13.3M | N/A | $14.1M+11.9% | $12.6M |
| Operating Income | -$50.7M-4.2% | -$48.6M+9.9% | -$54.0M-1.1% | -$53.4M-1.9% | -$52.4M | N/A | -$54.2M+2.6% | -$55.7M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | $0 | $0 | N/A | $0+100.0% | -$134K |
| Net Income | -$49.1M-6.6% | -$46.1M+8.9% | -$50.6M+3.8% | -$52.6M-1.4% | -$51.9M | N/A | -$52.5M+5.1% | -$55.3M |
| EPS (Diluted) | $-0.28 | N/A | $-0.32+22.0% | $-0.41-2.5% | $-0.40 | N/A | $-0.44+4.3% | $-0.46 |
PRME Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $294.7M-14.0% | $342.7M-11.0% | $385.0M+38.0% | $279.0M-15.0% | $328.2M+10.3% | $297.5M-10.6% | $332.8M+28.1% | $259.7M |
| Current Assets | $137.9M-23.9% | $181.3M-21.7% | $231.4M+90.8% | $121.3M-25.9% | $163.8M-22.7% | $211.9M-13.9% | $246.1M+44.1% | $170.8M |
| Cash & Equivalents | $64.1M+1.7% | $63.0M-11.7% | $71.4M+32.7% | $53.8M-41.4% | $91.9M-49.6% | $182.5M+54.7% | $118.0M+112.2% | $55.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $218.0M-1.7% | $221.9M-0.6% | $223.2M+2.3% | $218.1M-1.4% | $221.2M+53.3% | $144.4M+0.8% | $143.3M+127.0% | $63.1M |
| Current Liabilities | $36.3M-3.1% | $37.4M+6.9% | $35.0M+2.7% | $34.1M-0.5% | $34.3M-9.7% | $38.0M+0.2% | $37.9M+82.5% | $20.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $76.7M-36.5% | $120.9M-25.3% | $161.8M+165.9% | $60.9M-43.1% | $106.9M-30.2% | $153.1M-19.2% | $189.5M-3.6% | $196.6M |
| Retained Earnings | -$937.5M-5.5% | -$888.4M-5.5% | -$842.3M-6.4% | -$791.7M-7.1% | -$739.1M-7.6% | -$687.2M-6.6% | -$644.9M-8.9% | -$592.4M |
PRME Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$42.7M-14.6% | -$37.3M-6.3% | -$35.0M+15.4% | -$41.4M+15.2% | -$48.9M-400.8% | $16.2M+162.7% | -$25.9M+43.0% | -$45.5M |
| Capital Expenditures | $214K-26.2% | $290K+17.4% | $247K-84.3% | $1.6M-35.1% | $2.4M+35.2% | $1.8M+40.3% | $1.3M-32.9% | $1.9M |
| Free Cash Flow | -$42.9M-14.3% | -$37.5M-6.4% | -$35.3M+17.9% | -$43.0M+16.2% | -$51.3M-454.8% | $14.5M+153.2% | -$27.2M+42.6% | -$47.4M |
| Investing Cash Flow | $43.4M+53.2% | $28.3M+130.8% | -$92.1M-3424.5% | $2.8M+105.8% | -$47.7M-198.9% | $48.3M-4.1% | $50.3M+630.2% | $6.9M |
| Financing Cash Flow | $393K-30.1% | $562K-99.6% | $144.8M+73378.7% | $197K-96.7% | $6.0M+599900.0% | $1K-100.0% | $38.5M+109937.1% | $35K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PRME Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | -5800.5%-1394.5pp | -4406.0%+381.2pp | -4787.2%-1183.9pp | -3603.3% | N/A | -25948.3% | N/A |
| Net Margin | N/A | -5498.7%-1369.5pp | -4129.1%+587.5pp | -4716.7%-1147.9pp | -3568.8% | N/A | -25128.2% | N/A |
| Return on Equity | -64.0%-25.9pp | -38.1%-6.9pp | -31.3%+55.1pp | -86.4%-37.9pp | -48.5% | N/A | -27.7%+0.4pp | -28.1% |
| Return on Assets | -16.7%-3.2pp | -13.4%-0.3pp | -13.1%+5.7pp | -18.9%-3.0pp | -15.8% | N/A | -15.8%+5.5pp | -21.3% |
| Current Ratio | 3.80-1.0 | 4.84-1.8 | 6.61+3.1 | 3.56-1.2 | 4.78-0.8 | 5.58-0.9 | 6.50-1.7 | 8.23 |
| Debt-to-Equity | 2.84+1.0 | 1.84+0.5 | 1.38-2.2 | 3.58+1.5 | 2.07+1.1 | 0.94+0.2 | 0.76+0.4 | 0.32 |
| FCF Margin | N/A | -4480.4%-1599.9pp | -2880.5%+974.6pp | -3855.1%-328.3pp | -3526.8% | N/A | -13009.1% | N/A |
Similar Companies
Frequently Asked Questions
What is Prime Medicine's annual revenue?
Prime Medicine (PRME) reported $4.6M in total revenue for fiscal year 2025. This represents a 55.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Prime Medicine's revenue growing?
Prime Medicine (PRME) revenue grew by 55.3% year-over-year, from $3.0M to $4.6M in fiscal year 2025.
Is Prime Medicine profitable?
No, Prime Medicine (PRME) reported a net income of -$201.1M in fiscal year 2025, with a net profit margin of -4342.4%.
What is Prime Medicine's EBITDA?
Prime Medicine (PRME) had EBITDA of -$201.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Prime Medicine's operating margin?
Prime Medicine (PRME) had an operating margin of -4498.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Prime Medicine's net profit margin?
Prime Medicine (PRME) had a net profit margin of -4342.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Prime Medicine's return on equity (ROE)?
Prime Medicine (PRME) has a return on equity of -166.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Prime Medicine's free cash flow?
Prime Medicine (PRME) generated -$167.1M in free cash flow during fiscal year 2025. This represents a -28.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Prime Medicine's operating cash flow?
Prime Medicine (PRME) generated -$162.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Prime Medicine's total assets?
Prime Medicine (PRME) had $342.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Prime Medicine's capital expenditures?
Prime Medicine (PRME) invested $4.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Prime Medicine spend on research and development?
Prime Medicine (PRME) invested $160.6M in research and development during fiscal year 2025.
What is Prime Medicine's current ratio?
Prime Medicine (PRME) had a current ratio of 4.84 as of fiscal year 2025, which is generally considered healthy.
What is Prime Medicine's debt-to-equity ratio?
Prime Medicine (PRME) had a debt-to-equity ratio of 1.84 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Prime Medicine's return on assets (ROA)?
Prime Medicine (PRME) had a return on assets of -58.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Prime Medicine's cash runway?
Based on fiscal year 2025 data, Prime Medicine (PRME) had $63.0M in cash against an annual operating cash burn of $162.6M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Prime Medicine's Altman Z-Score?
Prime Medicine (PRME) has an Altman Z-Score of -3.54, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Prime Medicine's Piotroski F-Score?
Prime Medicine (PRME) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Prime Medicine's earnings high quality?
Prime Medicine (PRME) has an earnings quality ratio of 0.81x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Prime Medicine?
Prime Medicine (PRME) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.